TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23349532

Group type: EXPERIMENTAL
Intervention: Delayed emptying (after insertion; n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Immediate emptying (before insertion; n=100)
Number of subjects: 200
Study: 21311899

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 4570

Group type: EXPERIMENTAL
Intervention: Bivalirudin (in statin group)
Number of subjects: 4570

Group type: EXPERIMENTAL
Intervention: Bivalirudin (in non-statin group)
Number of subjects: 4570

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 4570
Study: 19646801

Group type: EXPERIMENTAL
Intervention: Exercise training (10-month supervised program, 3 times weekly)
Number of subjects: 59
Study: 18298872

Group type: EXPERIMENTAL
Intervention: Epidural infusion of levobupivacaine and clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lumbar plexus infusion of levobupivacaine and clonidine
Number of subjects: 60
Study: 15572990

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A injection + physiotherapy rehabilitation program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiotherapy rehabilitation program only
Number of subjects: 40
Study: 12847735

Group type: EXPERIMENTAL
Intervention: Topical and oral L-phenylalanine (100 mg/Kg/day and gel at 10%) with 0.025% clobetasol propionate at night, sunlight or UVA exposure
Number of subjects: 70
Study: 9240190

Group type: EXPERIMENTAL
Intervention: Interstitial radiofrequency therapy (IRFT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 50
Study: 8494011

Group type: EXPERIMENTAL
Intervention: Restricted protein diet
Number of subjects: 456

Group type: COMPARATOR
Intervention: Controlled protein diet
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Fast progressive CRI
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Slowly progressive CRI
Number of subjects: 456
Study: 3815009

Group type: EXPERIMENTAL
Intervention: iohexol, 350 mg I/ml (Omnipaque, Nycomed UK Ltd)
Number of subjects: 62

Group type: COMPARATOR
Intervention: iopamidol, 370 mg I/ml (Niopam, E. Merck Ltd)
Number of subjects: 62
Study: 11293560

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 100
Study: 31393518

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy (at least 2 years, with an option for 3 additional years for those without recurrence)
Number of subjects: 462

Group type: COMPARATOR
Intervention: No endocrine therapy (control group)
Number of subjects: 462
Study: 30345969

Group type: EXPERIMENTAL
Intervention: 38 percent silver diamine fluoride (SDF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Deionized water (Control)
Number of subjects: 40
Study: 27902588

Group type: EXPERIMENTAL
Intervention: Guideline-oriented hypertension management
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Normally therapy method (Control)
Number of subjects: 6000
Study: 25262111

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume measurement
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: EAT volume as a predictor
Number of subjects: 92
Study: 22483180

Group type: EXPERIMENTAL
Intervention: Lucerne cast
Number of subjects: 66

Group type: COMPARATOR
Intervention: Forearm cast
Number of subjects: 66
Study: 19962164

Group type: EXPERIMENTAL
Intervention: LVA
Number of subjects: 66

Group type: COMPARATOR
Intervention: CPB
Number of subjects: 66
Study: 18182463

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion (3 microg/kg/min for 6 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 19
Study: 16265968

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 6092

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 6092
Study: 12028325

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 2392

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2392

Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 2392
Study: 10626698

Group type: EXPERIMENTAL
Intervention: Activator Methods' relative leg-length evaluation
Number of subjects: 34
Study: 7797778

Group type: EXPERIMENTAL
Intervention: Rest left ventricular ejection fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak exercise ejection fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in ejection fraction from rest to exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients unable to exercise or those not having a rest study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison with Multicenter Postinfarction Research Group data
Number of subjects: 0
Study: 2109197

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg per day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 66
Study: 6989681

Group type: EXPERIMENTAL
Intervention: Encephabol (pyritinol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30265560

Group type: EXPERIMENTAL
Intervention: Food Immunoglobulin G-Based Elimination Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist group (Control)
Number of subjects: 0
Study: 28556498

Group type: EXPERIMENTAL
Intervention: High-salt diet (measured by urinary sodium concentration)
Number of subjects: 465
Study: 25943661

Group type: EXPERIMENTAL
Intervention: Euhydrated-not thirsty (EU-NT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Euhydrated-thirsty (EU-T)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dehydrated-not thirsty (DH-NT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dehydrated-thirsty (DH-T)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thirst condition (T)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Euhydrated (EU)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dehydrated (DH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Not thirsty (NT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Thirsty (T)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Completion time
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pacing profile
Number of subjects: 11
Study: 24439929

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on day 1 and day 8) plus Cisplatin (75 mg/m² on day 1)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 364

Group type: COMPARATOR
Intervention: Gemcitabine and Cisplatin
Number of subjects: 364
Study: 22959989

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 4 × 10(3) pfu
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 4 × 10(4) pfu
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 4 × 10(5) pfu
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study: 19576944

Group type: EXPERIMENTAL
Intervention: PPV‐23 (given 8 weeks after PCV‐7)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PPV‐23 (given 10 months after PCV‐7)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sequential pneumococcal immunization
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both sequential pneumococcal vaccine regimens
Number of subjects: 70
Study: 17576388

Group type: EXPERIMENTAL
Intervention: pegylated IFN
Number of subjects: 38

Group type: COMPARATOR
Intervention: standard IFN
Number of subjects: 38
Study: 15903358

Group type: EXPERIMENTAL
Intervention: Regular training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reserve training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 11262514

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Exposure and nonexposure-based behavior therapy
Number of subjects: 135
Study: 9555821

Group type: EXPERIMENTAL
Intervention: Tretinoin gel and cream containing polyolprepolymer‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream containing polyolprepolymer‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tretinoin gel containing polyolprepolymer‐2 and three tretinoin prototype creams containing polyolprepolymer‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin gel formulation containing polyolprepolymer‐2
Number of subjects: 0
Study: 7930484

Group type: EXPERIMENTAL
Intervention: Interleukin-6 plasma levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor alpha plasma levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 57
Study: 3063051

Group type: EXPERIMENTAL
Intervention: Ointments containing nystatin and/or fusidic acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31764962

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31553661

Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiation Therapy (WBRT)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 215
Study: 29103440

Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation (LLLI) applied at 3-week intervals; energy density of 7.5 J/cm2/point, applied at baseline and then repeated after 3 weeks for 2 more visits.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (no laser irradiation)
Number of subjects: 22
Study: 25830642

Group type: EXPERIMENTAL
Intervention: Paraspinal anesthetic block with 1% lidocaine without epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 23184014

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acid supplementation (2 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21788992

Group type: EXPERIMENTAL
Intervention: Anchoring stent (5F double-pigtail plastic stent)
Number of subjects: 33
Study: 19001559

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paroxetine (20 mg/d)
Number of subjects: 20
Study: 16440532

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 14676459

Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE and 2.5 mg MPA every other day
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.625 mg CEE and 2.5 mg MPA every day
Number of subjects: 84
Study: 11035973

Group type: EXPERIMENTAL
Intervention: Boazul cuff (tourniquet)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-tourniquet group
Number of subjects: 38
Study: 8783954

Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous cocktail of pethidine and diazepam
Number of subjects: 30
Study: 1728807

Group type: EXPERIMENTAL
Intervention: High-potency multivitamin-mineral supplement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6705484

Group type: EXPERIMENTAL
Intervention: Intravenous injections of propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous injections of phentolamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 0
Study: 31127413

Group type: EXPERIMENTAL
Intervention: Tube insertion combined with adenoidectomy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Simple tube insertion
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Tympanic membrane tube for less than 12 months
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Tympanic membrane tube for more than 12 months
Number of subjects: 184
Study: 28219477

Group type: EXPERIMENTAL
Intervention: Autologous incus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Titanium partial ossicular replacement prosthesis
Number of subjects: 20
Study: 26011427

Group type: EXPERIMENTAL
Intervention: Community level intervention
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Individual level intervention
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Community plus individual intervention
Number of subjects: 455

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 455

Group type: COMPARATOR
Intervention: All arms (including control)
Number of subjects: 455
Study: 23354414

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR) 0.5 l/day for 15 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR)
Number of subjects: 8
Study: 20644555

Group type: COMPARATOR
Intervention: 30 mg PI2 in a minidrink
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (minidrink without PI2)
Number of subjects: 24
Study: 19815144

Group type: EXPERIMENTAL
Intervention: Improved readability and processability form (MIC + SS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Improved readability form (MIC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: AAO informed consent form
Number of subjects: 60
Study: 17199056

Group type: EXPERIMENTAL
Intervention: Systematic depression treatment program delivered by specialized nurses over 12 months
Number of subjects: 329

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Systematic depression treatment program
Number of subjects: 329
Study: 15114435

Group type: EXPERIMENTAL
Intervention: 400 mg sulpiride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11978148

Group type: EXPERIMENTAL
Intervention: P. ginseng extract 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10400840

Group type: EXPERIMENTAL
Intervention: Positive SPT responses to pets
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Positive SPT responses to grass
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Positive SPT responses to mites
Number of subjects: 1859
Study: 7782594

Group type: EXPERIMENTAL
Intervention: Mezlocillin (150 mg/kg/12 h)
Number of subjects: 286
Study: 1777364

Group type: EXPERIMENTAL
Intervention: Transthoracic electrical bioimpedance (TEB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-imaging dual beam Doppler ultrasound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both TEB and Doppler methods
Number of subjects: 0
Study: 6265082

Group type: EXPERIMENTAL
Intervention: Intensive induction chemotherapy (high-dose cyclophosphamide, doxorubicin, and VP-16-213)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intensive induction chemotherapy
Number of subjects: 54
Study: 6741672

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham-smoking
Number of subjects: 10
Study: 31657255

Group type: EXPERIMENTAL
Intervention: RadioEar IP30 insert earphone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LZeqETSPL approach
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reference threshold levels of the insert earphone ER-3A
Number of subjects: 25
Study: 29462986

Group type: EXPERIMENTAL
Intervention: Standing desks and balance pads (IG) for 11 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standing desks and balance pads (IG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control class (CG) received lessons as usual
Number of subjects: 38
Study: 27578252

Group type: EXPERIMENTAL
Intervention: Orange juice with 5.5 g of added orange pomace fibre (OPF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole orange (WO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orange-flavoured beverage with low dose OPF (2.5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orange-flavoured beverage with high dose OPF (5.5 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (orange-flavoured beverage without fibre)
Number of subjects: 0
Study: 24935561

Group type: EXPERIMENTAL
Intervention: Supra-therapeutic dose of drugs (specific drugs not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New model based on change from baseline
Number of subjects: 0
Study: 22871351

Group type: EXPERIMENTAL
Intervention: Bivalent r-fHBP vaccine (20μg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bivalent r-fHBP vaccine (60μg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bivalent r-fHBP vaccine (200μg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bivalent r-fHBP vaccine
Number of subjects: 103
Study: 19548273

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 130
Study: 18257185

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with hyperbaric oxygenation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple hyperbaric oxygenation
Number of subjects: 60
Study: 15794113

Group type: EXPERIMENTAL
Intervention: Argyle (22 gauge metal needle)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insyte (24 gauge plastic cannula with a metal needle)
Number of subjects: 20
Study: 14599261

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both nicotine patch and bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10381299

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg (o.a.d. or b.i.d.)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 8603644

Group type: EXPERIMENTAL
Intervention: Comprehensive Medline search
Number of subjects: 308

Group type: COMPARATOR
Intervention: Basic Medline search
Number of subjects: 308
Study: 1677551

Group type: EXPERIMENTAL
Intervention: Topical administration of levocabastine (0.5 mg/mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical administration of levocabastine (2.0 mg/mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triprolidine (10 mg)
Number of subjects: 12
Study: 6343868

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: cimetidine
Number of subjects: 775

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 775
Study: 30845346

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (8 or 24 mmol KNO3)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Potassium chloride (KCl; placebo)
Number of subjects: 33
Study: 29695589

Group type: COMPARATOR
Intervention: low‐dose subcutaneous crenezumab 300 mg every 2 weeks (n = 184)
Number of subjects: 431

Group type: COMPARATOR
Intervention: high‐dose intravenous crenezumab 15 mg/kg every 4 weeks (n = 247)
Number of subjects: 431

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 431
Study: 27400947

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once per day
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Prednisone 5 mg twice per day
Number of subjects: 1028
Study: 24502769

Group type: EXPERIMENTAL
Intervention: Tonic and Phasic Alertness Training (TAPAT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Active control computer games condition
Number of subjects: 114
Study: 22102056

Group type: EXPERIMENTAL
Intervention: β-alanine (BA, 2×800 mg tablets, 3× daily; CarnoSyn®; n=13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL, 2×800 mg maltodextrin tablets, 3× daily; n=11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: β-alanine (BA)
Number of subjects: 24
Study: 20553661

Group type: EXPERIMENTAL
Intervention: Youth CD-ROM intervention plus parent component
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Youth CD-ROM intervention only
Number of subjects: 513

Group type: COMPARATOR
Intervention: Control
Number of subjects: 513
Study: 18090054

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 0
Study: 15817604

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² + carboplatin AUC 5 (arm B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Carboplatin AUC 5 (arm A)
Number of subjects: 81
Study: 12493094

Group type: EXPERIMENTAL
Intervention: Intervention group (nutrition education programmes)
Number of subjects: 926

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 926
Study: 9222866

Group type: EXPERIMENTAL
Intervention: RLP-cholesterol assay
Number of subjects: 0
Study: 3181146

Group type: EXPERIMENTAL
Intervention: i.v. etomidate (0.3 mg kg‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: thiopentone (4 mg kg‐1)
Number of subjects: 22
Study: 4853767

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate administered orally before and after major surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group of patients
Number of subjects: 0
Study: 31172828

Group type: EXPERIMENTAL
Intervention: Leucine (LEU) supplement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Leucine-enriched BCAA (LBCAA) supplement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard BCAA supplement
Number of subjects: 22
Study: 28727924

Group type: EXPERIMENTAL
Intervention: Manual therapy intervention, assessed at 2 weeks for pain reduction.
Number of subjects: 0
Study: 26198363

Group type: EXPERIMENTAL
Intervention: tDCS (cathodal to auditory cortex, anode over prefrontal cortex)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study: 23695221

Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA-enhanced MRC combined with T2w-MRC
Number of subjects: 99

Group type: COMPARATOR
Intervention: T2w-MRC
Number of subjects: 99
Study: 21858142

Group type: EXPERIMENTAL
Intervention: UpToDate
Number of subjects: 44

Group type: COMPARATOR
Intervention: PubMed Clinical Queries
Number of subjects: 44
Study: 19671126

Group type: EXPERIMENTAL
Intervention: 10-item diabetic foot infection wound score
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 8-item wound score (excluding discharge scores)
Number of subjects: 371